相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b
Daisuke Endo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Recent Advances in Antiviral Therapy for Chronic Hepatitis C
Akihiro Tamori et al.
MEDIATORS OF INFLAMMATION (2016)
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
Satoru Hashimoto et al.
PLOS ONE (2016)
Effect of Sofosbuvir and Ribavirin Treatment on Peripheral and Hepatic Lipid Metabolism in Chronic Hepatitis C Virus, Genotype 1-Infected Patients
Eric G. Meissner et al.
HEPATOLOGY (2015)
Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study
Makoto Daimon et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
From non-A, non-B hepatitis to hepatitis C virus cure
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2015)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Chronic hepatitis C virus infection and lipoprotein metabolism
Yoshio Aizawa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
Thomas Berg et al.
LIVER INTERNATIONAL (2015)
Update on hepatitis C: Direct-acting antivirals
Leon L. Seifert et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial
Masao Omata et al.
JOURNAL OF VIRAL HEPATITIS (2014)
HCV and Host Lipids: An Intimate Connection
Esperance A. K. Schaefer et al.
SEMINARS IN LIVER DISEASE (2013)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
The Effect of Antiviral Therapy on Serum Cholesterol Levels in Chronic Hepatitis C
Eun Sun Jang et al.
GUT AND LIVER (2011)
Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS)
Hironori Imano et al.
PREVENTIVE MEDICINE (2011)
Animal models in the study of hepatitis C virus-associated liver pathologies
Herve Lerat et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Twelve Weeks Posttreatment Follow-up Is as Relevant as 24 Weeks to Determine the Sustained Virologic Response in Patients with Hepatitis C Virus Receiving Pegylated Interferon and Ribavirin
Michelle Martinot-Peignoux et al.
HEPATOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection
Ching-Sheng Hsu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids: Implications for Long-Term Follow-Up
Kathleen E. Corey et al.
HEPATOLOGY (2009)
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data
Francesco Negro et al.
LIVER INTERNATIONAL (2009)
VX-950, a novel hepatitis C virus (HCV) NS34A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
K Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
分享论文
